1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag

Newbury Pharmaceuticals Secures Generic Approval for Buspiron

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Buspiron tablets in Sweden.

“Buspirone is a medication for anxiety (anxiolytic) that works by affecting certain natural substances in the brain (neurotransmitters). Based on this positive outcome of the regulatory process, we will proceed to launch this product” says Mr Lars Minor CEO of Newbury

 The annual value of the market is estimated to be 0,9 MEUR according to DLMI Nordic Pharma Insights.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals Secures Generic Approval for Buspiron

Datum 2024-10-28, kl 10:00
Källa MFN
Bifogade filer
Newbury Pharmaceuticals Secures Generic Approval for Buspiron
Affiliate
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet